Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

FDA Maintains U.S. Enrollment Hold On Newron's Phase 3 ENIGMA-TRS 2 Schizophrenia Study

(RTTNews) - Newron Pharmaceuticals (NP5.DE, NWRN.SW) said the U.S. Food and Drug Administration (FDA) has informed the company that a hold on the enrollment of new patients at U.S. sites participating in the Phase 3 ENIGMA-TRS 2 study of evenamide will remain in place.

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

Read the original at nasdaq.com →

More in Health & Medicine

Month-long rabies vaccination drive in Kozhikode from September 28

Vaccination drives will be organised through veterinary hospitals, veterinary dispensaries and ward-level camps in collaboration with various local self-government institutions.

  • Kozhikode begins rabies vaccination drive on September 28
  • Fourth phase of Rabies-Free Kerala campaign
  • Vaccination at veterinary hospitals, dispensaries, and ward camps

More from Sunday 27 September →